LearnGlossaryMarketStocksSuperinvestorsSign in

BNGO

Bionano Genomics, Inc.

Healthcare · $14M market cap

Verdict

We can't put a fair value on BNGO right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-39.1% a year✗
Sales growth20.8% a year✓
Free cash flow growth—?
Return on invested capital-44.2%✗

Follow BNGO

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 4, 2026: 1 open-market purchase worth $5K. Why purchases matter

Purchases

Luderer Albert

Interim Chief Executive · 2026-09-04

Bought

$5K

About Bionano Genomics, Inc.

Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a…

Medical - Instruments & Supplies

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works